NCOA3

Nuclear receptor coactivator 3 · Q9Y6Q9 · NCOA3 on Sugi Atlas →

67,258 patent compounds predicted against NCOA3, 48,027 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Triapine (SCHEMBL29370)	0.68	3/20
Triapine (SCHEMBL29371)	0.68	3/20
Irinotecan (SCHEMBL193504)	0.59	3/20
SCHEMBL237352	0.44	3/20
Teniposide (SCHEMBL3907)	1.00	2/20
Teniposide (SCHEMBL3908)	1.00	2/20
Etoposide (SCHEMBL4258)	1.00	2/20
Etoposide (SCHEMBL4259)	1.00	2/20
Teniposide (SCHEMBL94844)	1.00	2/20
Methylene Blue Cation (SCHEMBL127316)	1.00	2/20
Etoposide (SCHEMBL3622)	0.94	2/20
Etoposide (SCHEMBL43860)	0.86	2/20
Etoposide Phosphate (SCHEMBL3621)	0.83	2/20
SCHEMBL94972	0.81	2/20
Etoposide (SCHEMBL149785)	0.81	2/20
SCHEMBL172914	0.76	2/20
SCHEMBL160042	0.75	2/20
SCHEMBL95223	0.67	2/20
SCHEMBL129194	0.66	2/20
SCHEMBL25640	0.65	2/20

Clinical trials — most relevant to NCOA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer	PHASE2	RECRUITING
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer	PHASE2	COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer	PHASE2	COMPLETED
Meclizine for Hepatocellular Carcinoma	PHASE1	COMPLETED
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects	nan	UNKNOWN
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NCOA3 binder may also engage these)

Protein	Name	Similarity
O09000	—	1.000	O09000 →
O57539	—	0.996	O57539 →
NCOA1	Nuclear receptor coactivator 1	0.988	landscape →
P70365	—	0.988	P70365 →
Q4PJW2	—	0.987	Q4PJW2 →
Q9WUI9	—	0.982	Q9WUI9 →
NCOA2	Nuclear receptor coactivator 2 (NCoA-2) (Clas	0.981	landscape →
Q98TW1	—	0.980	Q98TW1 →
B5DE09	—	0.979	B5DE09 →
Q9P2N5	—	0.979	Q9P2N5 →
Q61026	—	0.979	Q61026 →
GATAD2B	Transcriptional repressor p66-beta	0.977	landscape →
P51514	—	0.977	P51514 →
Q60420	—	0.976	Q60420 →
P15881	—	0.976	P15881 →
Q80TM6	—	0.975	Q80TM6 →
Q5SFM8	—	0.975	Q5SFM8 →
TCF4	Transcription factor 4 (TCF-4) (Class B basic	0.975	landscape →
Q60722	—	0.975	Q60722 →
Q24767	—	0.974	Q24767 →
A0JNC2	—	0.974	A0JNC2 →
Q61286	—	0.974	Q61286 →
Q9Y2K5	—	0.973	Q9Y2K5 →
Q03297	—	0.973	Q03297 →
Q9W705	—	0.972	Q9W705 →
TCF12	Transcription factor 12	0.972	landscape →
Q9EPU2	—	0.972	Q9EPU2 →
Q62655	—	0.972	Q62655 →
Q8VHR5	—	0.971	Q8VHR5 →
Q9DCB4	—	0.971	Q9DCB4 →